(Q38223250)

31 August 2017

Myeloid-derived suppressor cell heterogeneity in human cancers (English)

1 reference

31 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Laura Pinton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Vera Damuzzo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Susanna Mandruzzato

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Ilaria Marigo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Vincenzo Bronte

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

1 June 2014

1 reference

Annals of the New York Academy of Sciences

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

1319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

47-65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immature myeloid cells and cancer-associated immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Coordinated regulation of myeloid cells by tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Control of immune response by amino acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

NOX enzymes and the biology of reactive oxygen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid cell diversification and complexity: an old concept with new turns in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Antigen specificity of immune suppression by myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Targeting oncogenic drivers and the immune system in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Melanoma-induced immunosuppression and its neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid-derived suppressor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Hepatocellular carcinoma from an immunologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Therapeutic targeting of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Enhancing the efficacy of cancer vaccines in urologic oncology: new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Editorial: PGE2-producing MDSC: a role in tumor progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Immune tolerance to tumor antigens occurs in a specialized environment of the spleen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Myeloid-derived suppressor cells in cancer: recent progress and prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Melanoma immunology: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12469

21 January 2018

Identifiers

DOI

10.1111/NYAS.12469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965257%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference